Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 168 Third Avenue WALTHAM MA 02451 |
Tel: | 1-781-6221111 |
Website: | https://www.thermofisher.com |
IR: | See website |
Key People | ||
Marc N. Casper Chairman of the Board, President, Chief Executive Officer | Stephen Williamson Chief Financial Officer, Senior Vice President | Michel Lagarde Chief Operating Officer, Executive Vice President |
Gianluca Pettiti Executive Vice President | Michael A. Boxer Senior Vice President, General Counsel | Joseph Holmes Chief Accounting Officer, Vice President |
Business Overview |
Thermo Fisher Scientific Inc. is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. The Company's Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Analytical Instruments segment provides instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. |
Financial Overview |
For the fiscal year ended 31 December 2023, Thermo Fisher Scientific Inc revenues decreased 5% to $42.86B. Net income decreased 14% to $6B. Revenues reflect Life Sciences Solutions segment decrease of 26% to $9.98B, Speciality Diagnostics segment decrease of 8% to $4.41B, North America segment decrease of 7% to $22.76B, Asia Pacific segment decrease of 3% to $7.87B, Europe segment decrease of less than 1% to $10.74B. |
Employees: | 122,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $247,758M as of Dec 31, 2023 |
Annual revenue (TTM): | $42,857M as of Dec 31, 2023 |
EBITDA (TTM): | $10,757M as of Dec 31, 2023 |
Net annual income (TTM): | $5,995M as of Dec 31, 2023 |
Free cash flow (TTM): | $6,404M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $26,837M as of Dec 31, 2023 |
Shares outstanding: | 381,312,268 as of Feb 3, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |